Jonathan Daniel Moses, MD
Gastroenterology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Moses’s office at (650) 498-7200 to ask if they take your plan before you enroll.
California Medical Board record
Licence A103720 · Current
Licensed to practise in California · since 2008 · expires 2027-04-30 · Ohio State University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 1-10 | None |
Medicaid work
$1,262 in 2024
Medicaid paid $1,262 for 12 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 12 | $1,262 |
| 2024 | 12 | 1 | 12 | $1,262 |
| 2023 | 213 | 4 | 26 | $4,025 |
| 2022 | 423 | 5 | 25 | $4,678 |
| 2021 | 283 | 5 | 22 | $7,243 |
| 2020 | 373 | 6 | 27 | $19,202 |
| 2019 | 219 | 3 | 15 | $8,172 |
| 2018 | 244 | 2 | 25 | $6,726 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 149 | $4,025 |
| Medication list documented in medical record (COA) | 26 | $0 |
| BODY MASS INDEX DOCD | 25 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 13 | $0 |
2022
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 172 | $4,678 |
| Medication list documented in medical record (COA) | 110 | $0 |
| BODY MASS INDEX DOCD | 77 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 38 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 26 | $0 |
2021
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 231 | $6,267 |
| Return visit (30+ min) | 15 | $976 |
| Medication list documented in medical record (COA) | 13 | $0 |
| BODY MASS INDEX DOCD | 12 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 12 | $0 |
2020
| Upper gastrointestinal endoscopy with biopsy | 28 | $11,144 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 275 | $7,265 |
| Return visit (30+ min) | 12 | $690 |
| Measurement of C-reactive protein | 15 | $62 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 15 | $41 |
| TISSUE EXAM BY PATHOLOGIST | 28 | $0 |
2019
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 151 | $4,128 |
| Return visit (30+ min) | 56 | $3,256 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 12 | $789 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 229 | $6,036 |
| Return visit (30+ min) | 15 | $690 |
Money from drug and device companies
$99 in 2025
| 2025 | 2 | 3 | None | $99 |
| 2023 | 2 | 12 | $3,850 | $4,056 |
| 2022 | 5 | 6 | None | $178 |
| 2021 | 2 | 12 | $2,750 | $2,994 |
| 2020 | 1 | 7 | None | $87 |
| 2019 | 1 | 6 | $5,500 | $5,753 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
See all 3 published payments
| Lilly USA | Meals · 2025-08-08 | Omvoh | $20 |
| Lilly USA | Meals · 2025-03-05 | Omvoh | $16 |
| Abbvie | Meals · 2025-02-05 | Rinvoq | $62 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $4,056
| Abbvie | Skyrizi | $4,019 | 11 payments
|
| Regeneron Healthcare Solutions | Dupixent | $37 | 1 payment
|
2022: $178
| Medtronic | Endoflip | $86 | 1 payment
|
| Abbvie | Humira | $37 | 2 payments
|
| Mirum Pharmaceuticals | Livmarli | $20 | 1 payment
|
| Celgene | Zeposia | $19 | 1 payment
|
| QOL Medical | Sucraid | $16 | 1 payment
|
2021: $2,994
| AbbVie | Humira | $2,979 | 11 payments
|
| QOL Medical | Sucraid | $15 | 1 payment
|
2020: $87
| AbbVie | Humira | $87 | 7 payments
|
2019: $5,753
| AbbVie | Humira | $5,753 | 6 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ABBVIE INC. · Study To Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately To Severely Active Ulcerative Colitis · 2025 | Their institution | $98,406 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Double-Blind, Phase 3 Study To Evaluate the Efficacy and Safety of Vedolizumab Intravenous As Maintenance Therapy in Pediatric Subjects With Moderately To Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy · 2023 | Their institution | $60,500 |
| ARENA PHARMACEUTICALS, INC. · An Openlabel Singlearm Study To Evaluate the Efficacy Pharmacokinetics and Safety of Etrasimod in Adolescent Subjects With Moderately To Severely Active Ulcerative Colitis · 2022 | Their institution | $30,725 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Double-Blind, Phase 3 Study To Evaluate the Efficacy and Safety of Vedolizumab Intravenous As Maintenance Therapy in Pediatric Subjects With Moderately To Severely Active Crohn'S Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy · 2023 | Their institution | $29,000 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Double-Blind, Phase 3 Study To Evaluate the Efficacy and Safety of Vedolizumab Intravenous As Maintenance Therapy in Pediatric Subjects With Moderately To Severely Active Crohn'S Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy · 2022 | Their institution | $28,500 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 2, Randomized, Double-Blind, Dose-Ranging Study To Determine the Pharmacokinetics, Safety and Tolerability of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis Or Crohn'S Disease · 2019 | Their institution | $25,750 |
| ABBVIE INC. · A Study To Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 To 17 Years With Ulcerative Colitis · 2023 | Their institution | $25,200 |
| Janssen Research & Development, LLC · A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab As Openlabel Intravenous Induction Treatment Followed By Randomized Double-Blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants With Moderately To Severely Active Ulcerative Colitis · 2022 | Their institution | $16,500 |
| Janssen Research & Development, LLC · A Phase 3 Study of the Efficacy Safety and Pharmacokinetics of Ustekinumab As Open Label Intravenous Induction Treatment Followed By Randomized Double Blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants With Moderately To Severely Active Crohn'S Disease · 2022 | Their institution | $16,500 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2 Study of Rpc-1063 in Patients With Ulcerative Colitis · 2024 | Their institution | $16,076 |
| Celgene Corporation · Induction Study #2 - A Phase 3, Multicenter, Rando · 2021 | Their institution | $15,250 |
| Celgene Corporation · A Phase 3, Multicenter, Randomized, Double-Blind, · 2021 | Their institution | $15,250 |
| Celgene Corporation · A Phase 3, Multicenter, Open-Label Extension Study · 2021 | Their institution | $15,250 |
| UCB SA · A Phase 3, Randomized, Double-Blind, Multicenter Study Including An Active Reference Arm To Evaluate Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents (6 To 17 Years of Age) With Moderately To Severely · 2021 | Their institution | $15,000 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 2, Randomized, Double-Blind, Dose-Ranging Study To Determine the Pharmacokinetics, Safety and Tolerability of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis Or Crohn'S Disease · 2021 | Their institution | $13,350 |
| Janssen Research & Development, LLC · A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab As Openlabel Intravenous Induction Treatment Followed By Randomized Double-Blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants With Moderately To Severely Active Ulcerative Colitis · 2023 | Their institution | $8,556 |
| Janssen Research & Development, LLC · A Phase 3 Study of the Efficacy Safety and Pharmacokinetics of Ustekinumab As Open Label Intravenous Induction Treatment Followed By Randomized Double Blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants With Moderately To Severely Active Crohn'S Disease · 2023 | Their institution | $8,288 |
| ABBVIE INC. · A Study To Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 To 17 Years With Ulcerative Colitis · 2024 | Their institution | $7,000 |
| Celgene Corporation · Phase II / III Pediatric Cd Study - A Phase 2/3, Multicenter, Randomized, Double-Blind Study To Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (Rpc1063) in Pediatric Participants With Moderately To Severely Active Cr · 2022 | Their institution | $6,616 |
| ABBVIE INC. · A Study To Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 To 17 Years With Ulcerative Colitis · 2025 | Their institution | $4,740 |
| Janssen Research & Development, LLC · Cnto1275crd3010 · 2023 | This clinician | $2,075 |
| ARENA PHARMACEUTICALS, INC. · An Openlabel Singlearm Study To Evaluate the Efficacy Pharmacokinetics and Safety of Etrasimod in Adolescent Subjects With Moderately To Severely Active Ulcerative Colitis · 2023 | Their institution | $850 |
| ABBVIE INC. · A Phase 3 Multicenter Study To Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib With Open-Label Induction, Randomized, Double-Blind Maintenance and Open-Label Long-Term Extension in Pediatric Subjects With Moderately To Severely Active Crohns Disease and Inadequate Response, Intolerance, Or Medical Contraindications To Corticosteroids, Immunosuppressants, and/Or Biologic Therapy · 2025 | Their institution | $93 |
Professional record
- NPI
- 1023254711
- Licence
- CA A103720California A103720: Current · expires 2027-04-30
- Trained
- Ohio State University College of Medicine, 2005
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0206X (2080P0206X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2008-12-30
- NPI last updated
- 2024-04-10
- NPI record certified
- 2024-04-10
This is when the NPI record was last certified, not a medical board exam.